Eradication of Hepatitis C Virus Is Associated With Reduction in Hematologic Malignancies: Major Differences Between Interferon and Direct‐Acting Antivirals

It is unclear whether eradication of hepatitis C virus (HCV) leads to a reduction in the risk of hematologic malignancies. We aimed to determine the impact of sustained virologic response (SVR) induced by either direct‐acting antivirals (DAAs) or interferon (IFN) on the risk of hematologic malignanc...

Full description

Bibliographic Details
Main Authors: George N. Ioannou, Pamela K. Green, Kristin Berry, Solomon A. Graf
Format: Article
Language:English
Published: Wiley 2019-08-01
Series:Hepatology Communications
Online Access:https://doi.org/10.1002/hep4.1389
id doaj-f806b64ffbb345188cd7d2733c4faae1
record_format Article
spelling doaj-f806b64ffbb345188cd7d2733c4faae12020-11-24T21:55:50ZengWileyHepatology Communications2471-254X2019-08-01381124113610.1002/hep4.1389Eradication of Hepatitis C Virus Is Associated With Reduction in Hematologic Malignancies: Major Differences Between Interferon and Direct‐Acting AntiviralsGeorge N. Ioannou0Pamela K. Green1Kristin Berry2Solomon A. Graf3Division of Gastroenterology, Department of Medicine Veterans Affairs Puget Sound Health Care System and University of Washington Seattle WAResearch and Development Veterans Affairs Puget Sound Health Care System Seattle WAResearch and Development Veterans Affairs Puget Sound Health Care System Seattle WADivision of Oncology, Department of Medicine Veterans Affairs Puget Sound Health Care System and University of Washington Seattle WAIt is unclear whether eradication of hepatitis C virus (HCV) leads to a reduction in the risk of hematologic malignancies. We aimed to determine the impact of sustained virologic response (SVR) induced by either direct‐acting antivirals (DAAs) or interferon (IFN) on the risk of hematologic malignancies. We identified 69,581 patients who initiated antiviral treatment in the Veterans Affairs national health care system from January 1, 1999, to December 31, 2015, including 40,410 (58%) IFN‐only regimens, 4,546 (6.5%) DAA + IFN regimens, and 24,625 (35%) DAA‐only regimens. We retrospectively followed patients to identify incident cases of hematologic malignancies or monoclonal gammopathy of unknown significance (MGUS), a premalignant precursor of multiple myeloma. Among patients treated with IFN, SVR was significantly associated with a reduction in the risk of lymphoma (adjusted hazard ratio [AHR], 0.70; 95% confidence interval [CI], 0.51‐0.97), multiple myeloma (AHR, 0.40; 95% CI, 0.20‐0.77), MGUS (AHR, 0.65; 95% CI, 0.42‐0.99), or all hematologic malignancies and MGUS combined (AHR, 0.67; 95% CI, 0.53‐0.84) over a mean follow‐up of 10.6 years. In contrast, among patients treated with DAA, SVR was not associated with the risk of lymphoma, multiple myeloma, MGUS, or all hematologic malignancies and MGUS combined (AHR, 1.08; 95% CI, 0.66‐1.78) during a mean follow‐up of 2.9 years. Neither IFN‐induced SVR nor DAA‐induced SVR was associated with risk of colon cancer or prostate cancer, which were chosen a priori as comparison/control malignancies. Conclusion: We describe novel strong associations between IFN‐induced SVR and lymphoma, multiple myeloma, MGUS, and all hematologic malignancies combined. Surprisingly, these associations were not observed with DAA‐induced SVR.https://doi.org/10.1002/hep4.1389
collection DOAJ
language English
format Article
sources DOAJ
author George N. Ioannou
Pamela K. Green
Kristin Berry
Solomon A. Graf
spellingShingle George N. Ioannou
Pamela K. Green
Kristin Berry
Solomon A. Graf
Eradication of Hepatitis C Virus Is Associated With Reduction in Hematologic Malignancies: Major Differences Between Interferon and Direct‐Acting Antivirals
Hepatology Communications
author_facet George N. Ioannou
Pamela K. Green
Kristin Berry
Solomon A. Graf
author_sort George N. Ioannou
title Eradication of Hepatitis C Virus Is Associated With Reduction in Hematologic Malignancies: Major Differences Between Interferon and Direct‐Acting Antivirals
title_short Eradication of Hepatitis C Virus Is Associated With Reduction in Hematologic Malignancies: Major Differences Between Interferon and Direct‐Acting Antivirals
title_full Eradication of Hepatitis C Virus Is Associated With Reduction in Hematologic Malignancies: Major Differences Between Interferon and Direct‐Acting Antivirals
title_fullStr Eradication of Hepatitis C Virus Is Associated With Reduction in Hematologic Malignancies: Major Differences Between Interferon and Direct‐Acting Antivirals
title_full_unstemmed Eradication of Hepatitis C Virus Is Associated With Reduction in Hematologic Malignancies: Major Differences Between Interferon and Direct‐Acting Antivirals
title_sort eradication of hepatitis c virus is associated with reduction in hematologic malignancies: major differences between interferon and direct‐acting antivirals
publisher Wiley
series Hepatology Communications
issn 2471-254X
publishDate 2019-08-01
description It is unclear whether eradication of hepatitis C virus (HCV) leads to a reduction in the risk of hematologic malignancies. We aimed to determine the impact of sustained virologic response (SVR) induced by either direct‐acting antivirals (DAAs) or interferon (IFN) on the risk of hematologic malignancies. We identified 69,581 patients who initiated antiviral treatment in the Veterans Affairs national health care system from January 1, 1999, to December 31, 2015, including 40,410 (58%) IFN‐only regimens, 4,546 (6.5%) DAA + IFN regimens, and 24,625 (35%) DAA‐only regimens. We retrospectively followed patients to identify incident cases of hematologic malignancies or monoclonal gammopathy of unknown significance (MGUS), a premalignant precursor of multiple myeloma. Among patients treated with IFN, SVR was significantly associated with a reduction in the risk of lymphoma (adjusted hazard ratio [AHR], 0.70; 95% confidence interval [CI], 0.51‐0.97), multiple myeloma (AHR, 0.40; 95% CI, 0.20‐0.77), MGUS (AHR, 0.65; 95% CI, 0.42‐0.99), or all hematologic malignancies and MGUS combined (AHR, 0.67; 95% CI, 0.53‐0.84) over a mean follow‐up of 10.6 years. In contrast, among patients treated with DAA, SVR was not associated with the risk of lymphoma, multiple myeloma, MGUS, or all hematologic malignancies and MGUS combined (AHR, 1.08; 95% CI, 0.66‐1.78) during a mean follow‐up of 2.9 years. Neither IFN‐induced SVR nor DAA‐induced SVR was associated with risk of colon cancer or prostate cancer, which were chosen a priori as comparison/control malignancies. Conclusion: We describe novel strong associations between IFN‐induced SVR and lymphoma, multiple myeloma, MGUS, and all hematologic malignancies combined. Surprisingly, these associations were not observed with DAA‐induced SVR.
url https://doi.org/10.1002/hep4.1389
work_keys_str_mv AT georgenioannou eradicationofhepatitiscvirusisassociatedwithreductioninhematologicmalignanciesmajordifferencesbetweeninterferonanddirectactingantivirals
AT pamelakgreen eradicationofhepatitiscvirusisassociatedwithreductioninhematologicmalignanciesmajordifferencesbetweeninterferonanddirectactingantivirals
AT kristinberry eradicationofhepatitiscvirusisassociatedwithreductioninhematologicmalignanciesmajordifferencesbetweeninterferonanddirectactingantivirals
AT solomonagraf eradicationofhepatitiscvirusisassociatedwithreductioninhematologicmalignanciesmajordifferencesbetweeninterferonanddirectactingantivirals
_version_ 1725861113879330816